Star Imaging and Path Lab Ltd
Incorporated in 2004, Star Imaging and Path Lab Limited is a healthcare company providing diagnostic services across a wide range of medical tests.[1]
- Market Cap ₹ 134 Cr.
- Current Price ₹ 77.0
- High / Low ₹ 152 / 46.0
- Stock P/E 6.96
- Book Value ₹ 66.6
- Dividend Yield 0.00 %
- ROCE 26.1 %
- ROE 23.6 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Stock is trading at 1.16 times its book value
- Company has a good return on equity (ROE) track record: 3 Years ROE 32.1%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has high debtors of 212 days.
- Working capital days have increased from 97.5 days to 146 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 69 | 58 | 79 | 82 | 86 | |
| 54 | 52 | 55 | 53 | 53 | |
| Operating Profit | 15 | 6 | 23 | 29 | 33 |
| OPM % | 21% | 10% | 30% | 35% | 39% |
| 0 | 0 | 1 | 0 | 1 | |
| Interest | 2 | 2 | 3 | 3 | 2 |
| Depreciation | 4 | 3 | 5 | 5 | 6 |
| Profit before tax | 9 | 1 | 16 | 21 | 26 |
| Tax % | 33% | 35% | 23% | 26% | 27% |
| 6 | 1 | 12 | 16 | 19 | |
| EPS in Rs | 41.93 | 3.87 | 82.80 | 11.80 | 11.07 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 14% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 222% |
| TTM: | 21% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -42% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 29% |
| 3 Years: | 32% |
| Last Year: | 24% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 14 | 17 |
| Reserves | 17 | 17 | 30 | 34 | 99 |
| 30 | 27 | 31 | 33 | 21 | |
| 10 | 16 | 20 | 18 | 17 | |
| Total Liabilities | 58 | 61 | 82 | 98 | 154 |
| 15 | 19 | 22 | 21 | 25 | |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| 43 | 42 | 60 | 77 | 128 | |
| Total Assets | 58 | 61 | 82 | 98 | 154 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 14 | 5 | 18 | -3 | 23 | |
| -4 | -7 | -7 | -7 | -13 | |
| -7 | -5 | 2 | -0 | 36 | |
| Net Cash Flow | 3 | -7 | 13 | -10 | 46 |
| Free Cash Flow | 10 | -2 | 11 | -7 | 13 |
| CFO/OP | 119% | 95% | 95% | 10% | 91% |
Ratios
Consolidated / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 85 | 110 | 152 | 226 | 212 |
| Inventory Days | |||||
| Days Payable | |||||
| Cash Conversion Cycle | 85 | 110 | 152 | 226 | 212 |
| Working Capital Days | 6 | -13 | 23 | 124 | 146 |
| ROCE % | 6% | 34% | 34% | 26% |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| B2C Revenue Share % ・Standalone data |
|
||||
| Number of Diagnostic Centers centers ・Standalone data |
|||||
| Total Tests Conducted tests ・Standalone data |
|||||
| CT Scans Performed tests ・Standalone data |
|||||
| MRI Scans Performed tests ・Standalone data |
|||||
| Pathology Tests Performed tests ・Standalone data |
|||||
| Team Size employees ・Standalone data |
|||||
| B2B Hospital Tie-ups tie-ups ・Standalone data |
|||||
Extracted by Screener AI
Documents
Announcements
-
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
- 22nd AGM voting results and scrutinizer report filed; two ordinary resolutions passed on 29 September 2026.
- Shareholder Meeting / Postal Ballot-Outcome of AGM
-
Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Commencement Of Commercial Operations Of CT Scan Facility At Faridabad, Haryana
- CT scan facility commenced commercial operations at Faridabad on 28 September 2026 under hospital tie-up.
-
Closure of Trading Window
- Trading window closed from 1 October 2026 until 48 hours after half-year results.
- Reg. 34 (1) Annual Report.
Concalls
-
May 2026Transcript PPT
Business Profile[1]
Star Imaging and Path Lab Limited (originally Janta X-Ray Clinic) is a Delhi-based diagnostic healthcare service provider offering pathology, radiology, cardiology, and neurology services. The company operates through B2C, B2B, and B2G models, with NABL-accredited facilities.